Tweet
Med Clin (Barc). 2019 May 3. pii: S0025-7753(19)30130-7. doi: 10.1016/j.medcli.2019.02.003. [Epub ahead of print]
Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study.
[Article in English, Spanish]
Richi P1, Mart?n MD2, Nav?o MT3, Gonz?lez-Hombrado L4, Salido M5, Llorente J6, Thuissard-Vasallo I7, Alcocer P8, Saa-Requejo CM9, Jim?nez-Diaz A10, Cebri?n L3, Lojo L3, Garc?a-Castro M4, Sanz-Rosa D7, Castro P5, Fern?ndez-Rodr?guez S11, Mart?nez de Aramayona MJ11, Steiner M10, Cobo T10, Garc?a-Fern?ndez C9, Fern?ndez-Castro M10, Illera ?10, Valverde R12, Mu?oz-Fern?ndez S10.
Author information
Abstract
BACKGROUND AND OBJECTIVES:
Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.
MATERIAL AND METHODS:
Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied.
RESULTS:
253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054).
CONCLUSIONS:
Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.
Copyright ? 2019 Elsevier Espa?a, S.L.U. All rights reserved.
KEYWORDS:
Anti-TNF; Autoimmune inflammatory diseases; Biological therapy; Enfermedades inflamatorias autoinmunes; Influenza vaccine; Rituximab; Terapia biol?gica; Vacuna contra la gripe
PMID: 31060878 DOI: 10.1016/j.medcli.2019.02.003
Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study.
[Article in English, Spanish]
Richi P1, Mart?n MD2, Nav?o MT3, Gonz?lez-Hombrado L4, Salido M5, Llorente J6, Thuissard-Vasallo I7, Alcocer P8, Saa-Requejo CM9, Jim?nez-Diaz A10, Cebri?n L3, Lojo L3, Garc?a-Castro M4, Sanz-Rosa D7, Castro P5, Fern?ndez-Rodr?guez S11, Mart?nez de Aramayona MJ11, Steiner M10, Cobo T10, Garc?a-Fern?ndez C9, Fern?ndez-Castro M10, Illera ?10, Valverde R12, Mu?oz-Fern?ndez S10.
Author information
Abstract
BACKGROUND AND OBJECTIVES:
Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.
MATERIAL AND METHODS:
Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season. ELISA was used to measure influenza antigen A and B antibodies, before and after vaccination. Demographic parameters, diagnosis and kind of treatment were recorded and their influence on the final serological status against influenza was studied.
RESULTS:
253 subjects were analyzed. After vaccination, 77% of participants presented detectable antibodies against antigen A and 50.6% of them had detectable antibodies against antigen B. Final seropositivity rate against antigen B antibodies increased from baseline (50.6% vs 43.5%, p<0.001). Anti-TNF drugs were associated with better response and rituximab with the worst (79.2% vs 55.0% for final seropositivity against antigen A, p=0.020). Vaccine response in the rituximab group tended to improve when the interval between the drug administration and the vaccination was at least 12 weeks (seropositivity rate 80.0% in those with the longer interval vs 25.0% in the other group, p=0.054).
CONCLUSIONS:
Among the patients on biological therapy vaccinated against influenza, anti-TNF therapy was identified as a predictive factor of final seropositivity. Rituximab presented a lower rate of final seropositivity, which could be increased with an accurate administration schedule.
Copyright ? 2019 Elsevier Espa?a, S.L.U. All rights reserved.
KEYWORDS:
Anti-TNF; Autoimmune inflammatory diseases; Biological therapy; Enfermedades inflamatorias autoinmunes; Influenza vaccine; Rituximab; Terapia biol?gica; Vacuna contra la gripe
PMID: 31060878 DOI: 10.1016/j.medcli.2019.02.003